FDA
-
-
-
-
-
-
-
Spectrum Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update
-
-
-
-
-
-
-
Spectrum Pharmaceuticals Announces Management Changes
-
-
-
-
-
-
-
Spectrum (SPPI) de-prioritizes poziotinib after receiving CRL from FDA, shares drop
-
-
-
-
-
-
-
Spectrum Pharmaceuticals to Report Third Quarter 2022 Financial Results and Provide Corporate Update
-
-
-
-
-
-
-
Spectrum Pharma (SPPI) Announces Debt Financing Agreement with SLR Capital Partners with $30 Million Funded at Closing
-
-
-
-
-
-
-
Spectrum Pharma (SPPI) Presents Additional Poziotinib Data
-
-
-
-
-
-
-
Spectrum Pharmaceuticals to Participate in Two Upcoming Investor Conferences
-
322,963 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

